Table 1.
Overview of current guidelines/recommendations for wearable cardioverter-defibrillator use published by professional societies
| Indications/recommendations | American Heart Association/American College of Cardiology [27] | European Society of Cardiology [9, 31] | German Cardiac Society [28] | Austrian Society of Cardiology [33] |
|---|---|---|---|---|
| After explantation, if reimplantation is not possible (e.g. infection) | IIa/B | IIb/C | IIa/C | |
| Patients on the waiting list for a heart transplant without an ICD | IIb/B | IIb/C | IIa/C | |
| Myocarditis and LVEF ≤ 35% and/or malignant arrhythmias | IIb/B | IIa/C | IIa | IIa/C |
| Patients with expected improvement of left ventricular function in non-ischaemic cardiomyopathy | IIb/B | IIb/C | IIb | IIb/C |
| Ischaemic cardiomyopathy and LVEF ≤ 35% (40 days after myocardial infarction, 40 days before and after PTCA, 90 days after surgical revascularization) | IIb/B | IIb/C | IIb | IIb/C |
| Potential prophylactic indication, definite diagnosis not yet established | IIb/C | |||
| Patients with HF who are at risk of sudden cardiac death for a limited period or as a bridge to an implanted device | IIb/B |